Drug Interaction Study Between Atovaquone and Antiretroviral Agents in HIV-1 Infected Patients
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Malarone® (atovaquone/proguanil) is frequently used in malaria prophylaxis. Unfortunately,
there are indications that certain anti-HIV agents may decrease atovaquone plasma levels by
induction of atovaquone metabolism.
For travelling HIV patients, the clinical consequences of these possible drug drug
interactions are serious, since a diminished exposure to the anti-malarial drug will result
in suboptimal prophylaxis of malaria and potential development of drug resistant strains of
Plasmodium falciparum.
The purpose of this study is to find out if HIV patients using HAART regimes with either
lopinavir/ritonavir, atazanavir/ritonavir or efavirenz have lower atovaquone plasma levels
than healthy volunteers after a single dose of atovaquone/proguanil.
Phase:
Phase 4
Details
Lead Sponsor:
Radboud University
Treatments:
Anti-Retroviral Agents Atovaquone Atovaquone, proguanil drug combination Proguanil